Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Rhythm Biosciences Ltd, an Australian firm specializing in pioneering cancer diagnostic technologies, has successfully closed a shortfall offer related to their recent rights issue, raising a total of $2,745,416. The company expressed gratitude to both new and existing shareholders for their participation. This capital raise is aimed at advancing the development and distribution of their ColoSTAT® Test-Kit for early detection of colorectal cancer, which is based on significant research and has international patent protection.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.